Since low levels of miR-200c are associated with chemoresistance, high ZEB1 levels, and EMT in advanced breast and ovarian cancer, restoration of its expression is considered as a promising therapeutic approach to overcome limited therapeutic response (Cochrane et al., 2009). This evidence concerns the gene ZEB1 and ovarian cancer.